| SoC | Standard of care |
| ER | Oestrogen receptor |
| PR | Progesterone receptor |
| HER2 | Human epidermal growth factor receptor 2 |
| pCR | Pathological complete response |
| TOP2A | Topoisomerase II alpha |
| PTEN | Phosphatase and TENsin Homologue |
| EGFR | Epidermal Growth Factor Receptor |
| IGF1R | Insulin-like Growth Factor 1 Receptor |
| mTOR | Mammalian Target of Rapamycin |
| PNL | Purely non-invasive lesions |
| CEIN | Co-existing invasive cancer |
| DCIS | Ductal carcinoma in situ |
| TMA | Tissue microarray |
| TNBC | Triple negative breast cancer |
| IHC | Immunohistochemistry |
| N | Patient number |
| n | Event number |
| FFPE | Formalin-fixed paraffin-embedded |
| H-score | Histochemical score |
| AUC | Area under the curve |
| DDRD | DNA damage response deficiency |
| FA/BRCA | Fanconi anaemia/BRCA |
| WSIs | Whole-slide images |
| AI | Artificial intelligence |